|Anti-Human CD20 Recombinant Antibody (rituximab)
- Product Overview
- Recombinant monoclonal antibody to Human CD20. Rituximab (trade names rituximab and rituximab) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells (this should not be confused with pancreatic β- or beta cells). Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
- Human lymphoblastoid cell line SB
- Suitable for use in Neut, ELISA, IF, IP, FuncS, FC, WB and most other immunological methods.
- Specific Activity
- Tested positive against native human antigen
- Protein Construction
- Immunoglobulin G1,anti-(human CD20 (antigen)) (human-mouse monoclonal C2B8 gamma 1-chain), disulfide with human-mouse monoclonal C2B8 kappa-chain, dimer
- Predicted N terminal
- H Chain: QVQLQQPL Chain: QIVLSQS
- >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
- Store it under sterile conditions at -20°C upon receiving. Recommend to pack the protein into smaller quantities for optimal storage.
- Antigen Description
- CD20 is B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells.
- epidermal growth factor receptor binding;
- MS4A1; membrane-spanning 4-domains, subfamily A, member 1; CD20; B-lymphocyte antigen CD20; B1; Bp35; MS4A2; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1; S7; CVID5; LEU-16; MGC3969;
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.